Januvia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP-4 inhibitors: population-based cohort study
Clin Pharmacol Ther. 2023 Jun 16. doi: 10.1002/cpt.2975. Online ahead of print.ABSTRACTDipeptidyl peptidase-4 inhibitors (DPP-4i) interact with sulfonylureas to increase their risk of hypoglycemia. Our population-based study assessed whether intra-class pharmacologic heterogeneity among sulfonylureas (long- versus short-acting) and DPP-4i (peptidomimetic versus non-peptidomimetic) modifies this interaction. We conducted a cohort study using the UK's Clinical Practice Research Datalink Aurum linked to hospitalization and vital statistics data. We assembled a cohort of patients initiating sulfonylureas (2007-2020). Using a t...
Source: Clinical Pharmacology and Therapeutics - June 16, 2023 Category: Drugs & Pharmacology Authors: Jenny Dimakos Ying Cui Robert W Platt Christel Renoux Kristian B Filion Antonios Douros Source Type: research

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations
ConclusionTriple FDC of DAPA + SITA + MET ER tablets once daily was significantly better in achieving glycemic control versus dual combination once daily in patients with type 2 diabetes poorly controlled with metformin without any significant safety concerns.Trial RegistrationCTRI/2021/11/038176, registered on 22 November 2021. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study
In conclusion, in chronically ischemic myocardium, sitagliptin improves myocardial perfusion and arteriolar collateralization via the activation of pro-arteriogenic signaling pathways. (Source: Physiological Reports)
Source: Physiological Reports - June 11, 2023 Category: Physiology Authors: Sharif A. Sabe, Dwight Douglas Harris, Mark Broadwin, Mohamed Sabra, Cynthia M. Xu, Debolina Banerjee, M. Ruhul Abid, Frank W. Sellke Tags: ORIGINAL ARTICLE Source Type: research

The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Biochem Pharmacol. 2023 Jun 6:115637. doi: 10.1016/j.bcp.2023.115637. Online ahead of print.ABSTRACTAsymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis. We aimed to investigate whether the cardioprotective and antifibrotic effects of incretin drugs, exenatide and sitagliptin, may be associated with their ability to affect circulating and cardiac ADMA metabolism. Normal and fructose-fed rats were treated with sitagliptin (5.0/10 mg/kg) or exenatide (5/10 µ...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: G W ójcicka A Pradiuch E Fornal A Stachniuk A Korolczuk B Marzec-Kotarska H Nikolaichuk G Czechowska A Kozub A Trzpil A G óralczyk J Be łtowski Source Type: research

DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship
In conclusion, the direct effects of DPP-4 inhibitors or indirect effects through increasing circulating GLP-1 levels could be an effective therapeutic strategy in treating PD patients through modulation of neuroinflammation, oxidative stress, mitochondrial dysfunction, and neurogenesis.PMID:37269487 | DOI:10.1007/s43440-023-00500-5 (Source: Pharmacological Reports)
Source: Pharmacological Reports - June 3, 2023 Category: Drugs & Pharmacology Authors: Mohammed Alrouji Hayder M Al-Kuraishy Ali K Al-Buhadily Ali I Al-Gareeb Engy Elekhnawy Gaber El-Saber Batiha Source Type: research

CO193 Replication of Mini-Sentinel Saxagliptin Study Assessing Acute Myocardial Infarction Using Electronic Medical Record Network
In 2009, the US Food and Drug Administration (FDA) initiated a routine prospective surveillance study using the Mini-Sentinel (M-S) program to assess potential signals of acute myocardial infarction (AMI) with use of saxagliptin, an antihyperglycemic drug of the dipeptydal-peptidase 4 (DPP-4) inhibitor class, designated for the treatment of type 2 diabetes, compared with sitagliptin, pioglitazone, second-generation sulfonylureas, and long-acting insulin. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: K. Nikolli, J.B. Nikolli, E.E. Noss, T. Sagarino Source Type: research

CO191 Clinical Effectiveness and Cost-Analysis of New Oral Antidiabetics in a Cohort of Type 2 Diabetic Patients from a Cardiovascular Risk Program in Colombia
The objective was to analyze clinical outcomes and costs of patients in the year before and after the new medication was introduced. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: E. Echeverri, Á.J. Ruiz, M. Rondon, S. Echeverri, D. Rosselli Source Type: research

EE7 The Importance of Considering Price Metrics and Market Dynamics in US Economic Evaluations: The Case of Sglt-2 Inhibitors in the Treatment of Type 2 Diabetes (T2D)
In the US T2D market, prices reflect both branded and generic competition, within and across classes. Despite recommendations, comparative economic analyses usually hold relative prices constant and, equally unrealistic, often use list prices. Even the few analyses that use prices net of manufacturer rebates understate opportunity costs by excluding time-varying intermediary margins. We illustrate the implications of these choices by simulating canagliflozin 300mg vs. sitagliptin 100mg in treating T2D. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M. Willis, C. Neslusan, A. Nilsson Source Type: research